Overview
A purine base and a fundamental unit of adenine nucleotides.
Indication
For nutritional supplementation, also for treating dietary shortage or imbalance
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|
No clinical trials found
No clinical trials found for this drug
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Terumo BCT, Ltd | 14537-833 | INTRAVENOUS | 0.03 g in 100 mL | 12/15/2021 | |
| Terumo Corporation | 53877-001 | INTRAVENOUS | 0.275 g in 1000 mL | 12/7/2018 | |
| Haemonetics Corporation | 53157-736 | INTRAVENOUS | 0.017 g in 63 mL | 7/19/2023 | |
| Terumo Corporation | 53877-001 | INTRAVENOUS | 0.275 g in 1000 mL | 12/7/2018 | |
| Terumo BCT, Ltd | 14537-828 | INTRAVENOUS | 0.03 g in 100 mL | 7/18/2018 | |
| Fenwal, Inc. | 0942-9394 | INTRAVENOUS | 17.3 mg in 63 mL | 11/1/2022 | |
| Fenwal, Inc. | 0942-6326 | INTRAVENOUS | 19.3 mg in 70 mL | 8/27/2014 | |
| Fenwal, Inc. | 0942-6307 | INTRAVENOUS | 19.3 mg in 70 mL | 11/18/2019 | |
| Terumo BCT, Ltd | 14537-824 | INTRAVENOUS | 0.03 g in 100 mL | 7/18/2018 | |
| Haemonetics Corporation | 53157-124 | INTRAVENOUS | 0.033 g in 110 mL | 1/2/2020 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| SAG-M | 02386925 | Solution - 0-Unassigned | 0.0169 % / W/V | 1/20/2013 | |
| ADDITIVE SOLUTION FORMULA 3 AS-3 | 02324393 | Solution - 0-Unassigned | 0.030 G / 100 ML | 5/31/2013 | |
| CPD ADENINE CPDA 1 | fenwal labs, division of baxter corporation | 00516775 | Liquid - Intravenous | 28 MG / 100 ML | 12/31/1981 |
| ANTICOAGULANT CIT PHOS DEX ADENINE SOL USP | baxter corporation | 01960865 | Solution - Intravenous | 17.3 MG / 63 ML | 10/17/1996 |
| SAG-MANNITOL SOLUTION | laboratorios grifols s.a. | 02421143 | Solution - 0-Unassigned | 16.9 MG / 100 ML | N/A |
| ADDITIVE SOLUTION SODIUM ADENINE GLUCOSE MANNITOL (SAGM) | maco pharma | 02444097 | Solution - 0-Unassigned | 0.169 G / L | 8/22/2016 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.